LPA1-silenced MSCs showed a delayed progression of MM and tumour-related angiogenesis in vivo, while LPA3-silenced MSCs significantly promoted the progression of MM and tumour-related angiogenesis in vivo. This evidence concerns the gene LPAR3 and Miyoshi myopathy.